FDA approves Verigene test for warfarin (Coumadin) metabolism
The Verigene Warfarin Metabolism Nucleic Acid Test, from Nanosphere, that detects variants in CYP2C9 and VKORC1 genes, has been approved by the FDA. The test helps clinicians determine which patients may not metabolize warfarin normally due to a gene variation. In August, the FDA updated the prescribing information to include an explanation on how the variants can affect metabolism of the drug.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.